1,617 Shares in Insulet Co. (NASDAQ:PODD) Bought by Chesapeake Capital Corp IL

Chesapeake Capital Corp IL purchased a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 1,617 shares of the medical instruments supplier’s stock, valued at approximately $422,000.

Other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter valued at about $36,000. SRS Capital Advisors Inc. grew its position in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares during the last quarter. Friedenthal Financial bought a new stake in shares of Insulet in the 4th quarter valued at about $57,000. TD Private Client Wealth LLC grew its position in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the last quarter. Finally, Assetmark Inc. grew its position in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 246 shares during the last quarter.

Analyst Ratings Changes

PODD has been the topic of a number of analyst reports. Citigroup upped their price target on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Stifel Nicolaus upped their target price on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Raymond James restated an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, Canaccord Genuity Group upped their target price on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Stock Performance

Shares of Insulet stock opened at $260.47 on Wednesday. The company has a market cap of $18.29 billion, a PE ratio of 44.99, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The business has a 50 day moving average price of $272.30 and a 200-day moving average price of $256.12. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Equities analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.